<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02200094</url>
  </required_header>
  <id_info>
    <org_study_id>502.361</org_study_id>
    <nct_id>NCT02200094</nct_id>
  </id_info>
  <brief_title>Micardis®. Observational Study in Patients With Essential Hypertension</brief_title>
  <official_title>Micardis®. Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This study is designed to supplement, under conditions of usual clinical practice, the data
      on the efficacy and safety of Micardis® collected during the clinical studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <primary_completion_date type="Actual">October 2000</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in systolic and diastolic blood pressure</measure>
    <time_frame>Baseline, 4 weeks and 3 months after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with dose titration to 80 mg</measure>
    <time_frame>4 weeks and 3 months after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 3 months after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Global evaluation of treatment compliance by investigator, a 6-point rating scale</measure>
    <time_frame>4 weeks and 3 months after start of treatment</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4532</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Outpatients with essential hypertension</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose of Telmisartan, once daily</intervention_name>
    <arm_group_label>Outpatients with essential hypertension</arm_group_label>
    <other_name>Micardis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose of Telmisartan, once daily</intervention_name>
    <arm_group_label>Outpatients with essential hypertension</arm_group_label>
    <other_name>Micardis®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients over 18 years of age suffering essential hypertension, treated by general
        practitioners and/or specialists
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of either sex over the age of 18 years suffering from essential hypertension
             requiring treatment according to the physician

        Exclusion Criteria:

          -  Hypersensitivity to the active component or to any of the excipients

          -  Pregnancy and lactation

          -  Biliary obstructive disorders

          -  Severe hepatic impairment

          -  Severe renal impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2014</study_first_submitted>
  <study_first_submitted_qc>July 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2014</study_first_posted>
  <last_update_submitted>July 24, 2014</last_update_submitted>
  <last_update_submitted_qc>July 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

